利拉鲁肽与格列美脲联合二甲双胍治疗2型糖尿病的疗效及安全性

Therapeutic effect and safety of liraglutide and glimepiride combined with metformin in the treatment of type 2 diabetes

目的比较利拉鲁肽与格列美脲联合二甲双胍对2型糖尿病的疗效与安全性。方法选择96例2型糖尿病患者,随机分为对照组、低剂量组和高剂量组。三组患者均给予二甲双胍治疗。在此基础上,对照组给予格列美脲口服治疗,低剂量组和高剂量组给予不同剂量利拉鲁肽皮下注射治疗。比较三组患者治疗效果。结果治疗后,三组患者的治疗总有效率、疗效分布情况及胃肠道不良反应发生率比较,均无显著差异(P>0.05)。对照组低血糖事件发生率明显高于高剂量组与低剂量组(P<0.05)。治疗后,各组患者FBG、2 h PBG、HbA1c、BMI明显降低,且高剂量组均低于低剂量组,低剂量组和高剂量组FBG、HbA1c、BMI均明显低于对照组(P<0.05)。结论利拉鲁肽联合二甲双胍对2型糖尿病患者血糖与体质量控制效果优于格列美脲,低血糖事件发生率低,具推广价值。

Objective To compare the therapeutic effect and safety of liraglutide and glimepiride combined with metformin in type 2 diabetes.Methods Ninety-six patients with type 2 diabetes were selected and randomly divided into control group, low-dose group and high-dose group. Patients in this study were given metformin, on this basis, the control group received glimepiride oral treatment, the low-dose group and the high-dose group received different-dose liraglutide through hypodermic injection respectively. The clinical effects in the three groups were compared.Results After treatment,there were no significant differences in the total treatment efficacy, efficacy distribution and incidences of gastrointestinal adverse reactions among the three groups（P〈0.05）. The incidence of hypoglycemic events in the control group was significantly higher than those in the high-dose group and the low-dose group（P〈0.05）. After treatment, the FBG, 2 h PBG, HbA1c and BMI in the three groups significantly reduced, those in the high-dose group were lower than the low-dose group, the FBG, HbA1c and BMI in the high-dose group and the low-dose group were lower than those in the control group（P〈0.05）.Conclusion Liraglutide combined with metformin in type 2 diabetes has superior control effect of blood glucose and BMI to glimepiride, with low incidence of hygpoglycemia events, which has clinical spread value.